Home Featured Page 130

Featured

Latest

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

5-HT2A Virtual Chemical Screen Produces New Candidate Antidepressants

PT371 – The Trickster Archetype and the Need for Comic Relief

Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday,...

Eyes on Oregon: Special Edition

MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial...

Opinions | The Facts on Colorado Proposition 122

PT370 – Prohibition, Civil Disobedience, and The Coca Leaf Cafe

Webinar – The Dark Side of Psychedelic Therapies

Psychedelic Bulletin #122: Lusaris Raises $60m to Develop 5-MeO-DMT; First Take-Home...

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

1...129130131...301 Page 130 of 301

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA...

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

5-HT2A Virtual Chemical Screen Produces New Candidate Antidepressants

PT371 – The Trickster Archetype and the Need for Comic Relief

Reunion Neuroscience Schedules Fiscal Second Quarter 2023 Conference Call for Monday,...

Eyes on Oregon: Special Edition

MindMed to Host Earnings Call to Discuss Third Quarter 2022 Financial...

Opinions | The Facts on Colorado Proposition 122

PT370 – Prohibition, Civil Disobedience, and The Coca Leaf Cafe

Webinar – The Dark Side of Psychedelic Therapies

Psychedelic Bulletin #122: Lusaris Raises $60m to Develop 5-MeO-DMT; First Take-Home...

COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights

EDITOR PICKS

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA...

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY